Indeed, HPRT1, an enzyme that uses hypoxanthine metabolite to recycle purines (in order to be more efficient in DNA and RNA synthesis), predicts clinical outcome and controls gene expression in breast cancer [50]. This evidence concerns the gene HPRT1 and breast cancer.